The ‘precautionary principle’ as a guide for future drug development
Identifieur interne : 001908 ( Istex/Checkpoint ); précédent : 001907; suivant : 001909The ‘precautionary principle’ as a guide for future drug development
Auteurs : S. Alban [Allemagne]Source :
- European Journal of Clinical Investigation [ 0014-2972 ] ; 2005-03.
Abstract
During the last decade, the ‘precautionary principle’ health has gained importance. It is an approach to manage uncertain risks and to prevent any damage to the environment or human. A key element is to take action, even if some cause and effect relationships are not fully established scientifically. Although there are also critics of this principle, it is meanwhile, also increasingly implemented in medicine. An important subject is medicinal products of human or animal origin. Manifold official precaution‐guided regulations have been stated to improve their safety, particularly to avoid any infection by viruses and pathogens causing transmissible spongiform encephalopathies. In addition to numerous regulations and decisions, it is generally recommended to substitute animal and human‐derived products with adequate alternatives wherever possible. This is a great challenge for research and drug development. One option is recombinant proteins, which however, are not generally free of any risk of contamination. Therefore, the best strategy might be the development of synthetic, specifically acting drugs. The most widely used medicinal product of animal origin at present is heparin. Although there has been no indication of any viral contamination, many other reasons suggest its substitution by alternative antithrombotics. These actually promoted the research on new anticoagulants. With the approval of fondaparinux, the first synthetic, selective factor Xa, a first alternative to the porcine‐derived heparin has become available. In addition, other synthetic antithrombotics are currently in clinical development. In principle, it is thus possible that the prophylaxis and therapy of thromboembolic diseases will become completely independent of animal‐derived drugs, which would be in line with the precautionary principle.
Url:
DOI: 10.1111/j.0960-135X.2005.01455.x
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:7534B971C8D24AD87FDC5138BF497B52DC47E216Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The ‘precautionary principle’ as a guide for future drug development</title><author><name sortKey="Alban, S" sort="Alban, S" uniqKey="Alban S" first="S." last="Alban">S. Alban</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7534B971C8D24AD87FDC5138BF497B52DC47E216</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1111/j.0960-135X.2005.01455.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TFB35371-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000F02</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F02</idno><idno type="wicri:Area/Istex/Curation">000F02</idno><idno type="wicri:Area/Istex/Checkpoint">001908</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001908</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The ‘precautionary principle’ as a guide for future drug development</title><author><name sortKey="Alban, S" sort="Alban, S" uniqKey="Alban S" first="S." last="Alban">S. Alban</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Christian‐Albrechts‐University of Kiel</wicri:regionArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">European Journal of Clinical Investigation</title><title level="j" type="alt">EUROPEAN JOURNAL OF CLINICAL INVESTIGATION</title><idno type="ISSN">0014-2972</idno><idno type="eISSN">1365-2362</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">s1</biblScope><biblScope unit="page" from="33">33</biblScope><biblScope unit="page" to="44">44</biblScope><biblScope unit="page-count">12</biblScope><publisher>Blackwell Publishing, Ltd.</publisher><pubPlace> Oxford, UK</pubPlace><date type="published" when="2005-03">2005-03</date></imprint><idno type="ISSN">0014-2972</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2972</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">During the last decade, the ‘precautionary principle’ health has gained importance. It is an approach to manage uncertain risks and to prevent any damage to the environment or human. A key element is to take action, even if some cause and effect relationships are not fully established scientifically. Although there are also critics of this principle, it is meanwhile, also increasingly implemented in medicine. An important subject is medicinal products of human or animal origin. Manifold official precaution‐guided regulations have been stated to improve their safety, particularly to avoid any infection by viruses and pathogens causing transmissible spongiform encephalopathies. In addition to numerous regulations and decisions, it is generally recommended to substitute animal and human‐derived products with adequate alternatives wherever possible. This is a great challenge for research and drug development. One option is recombinant proteins, which however, are not generally free of any risk of contamination. Therefore, the best strategy might be the development of synthetic, specifically acting drugs. The most widely used medicinal product of animal origin at present is heparin. Although there has been no indication of any viral contamination, many other reasons suggest its substitution by alternative antithrombotics. These actually promoted the research on new anticoagulants. With the approval of fondaparinux, the first synthetic, selective factor Xa, a first alternative to the porcine‐derived heparin has become available. In addition, other synthetic antithrombotics are currently in clinical development. In principle, it is thus possible that the prophylaxis and therapy of thromboembolic diseases will become completely independent of animal‐derived drugs, which would be in line with the precautionary principle.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Alban, S" sort="Alban, S" uniqKey="Alban S" first="S." last="Alban">S. Alban</name></noRegion><name sortKey="Alban, S" sort="Alban, S" uniqKey="Alban S" first="S." last="Alban">S. Alban</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001908 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001908 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:7534B971C8D24AD87FDC5138BF497B52DC47E216
|texte= The ‘precautionary principle’ as a guide for future drug development
}}
| This area was generated with Dilib version V0.6.33. |  |